The effect of immunomodulators on the immunogenicity of TNF-blocking therapeutic monoclonal antibodies: a review

Table 1 Frequency of reported antibodies to infliximab and adalimumab in various inflammatory diseases

Inflammatory disease	ATIs, percentage	AAAs, percentage	References
Rheumatoid arthritis	8-52	12-44	[2–9]
Crohn disease	14-75	2.6-17	[10–17]
Juvenile idiopathic arthritis	NA	17	[18]
Ankylosing spondylitis	29	31	[19, 20]
Psoriatic arthritis	NA	18	[21]
Psoriasis	NA	45	[22]

ISSN: 1478-6362